Gala vs Pallas Health
Pallas Health's tirzepatide arrives as $897 every twelve weeks after a $179 opener; Gala's is a yearly rate for doses below the trial schedule.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Gala
Partner
$199/mo
One compounded program covers both molecules at $199 a month with every dose included, and the $179 printed beside it buys a year up front. Gala sells brand Ozempic alongside it at $1,299, so the two figures on the page are different products rather than two tiers of one.
- One price covers either molecule, with every dose included
- The yearly rung is labeled as a yearly subscription
- Provider visit, support and shipping stated as included
- All fifty states; FSA and HSA accepted
- No milligram strength published beside any price
- The $179 that leads the page requires a year up front
- Brand Ozempic at $1,299 sits beside the compounded rate
- Compounding pharmacy is not named
Pick it for: A low-dose year you have chosen deliberately
Not for: Anyone who needs the milligram strength stated before paying.
Pallas Health
Editorial
$325/mo
$199 and $299, flat as doses rise, across fifty-one states. A clean 50% step between the molecules.
- Provider care and check-ins included rather than billed on top
- Flat at every dose on both molecules
- The quarterly figure is published, so the average can be checked
- 51 jurisdictions
- The advertised monthly figure is never actually charged
- $597 lands as one charge, not three
- A reduced first month makes the early bill unrepresentative
- Injection only
Pick it for: Quarterly cash, and a rate that holds as doses rise
Not for: Anyone budgeting month to month, where the cycle matters more than the average.
Our verdict
Pallas advertises $299 a month for tirzepatide, which is $897 divided by three — and twelve weeks is 2.76 calendar months, not three, so the real rate is higher and the cash has to be there quarterly. Gala's figure is steady; the dose behind it is not. Gala states plainly that its protocol sits below the standard escalation, which is a different regimen from the one the tirzepatide trials ran — ask what milligram a year at $149 buys.
What actually separates them
Gala and Pallas Health differ on published price and where you can use it. The table summarizes those terms; confirm any details it does not cover with the provider.
Pallas Health’s comparison figure is $126 higher than Gala’s — a 63% difference between the listed rates. These figures do not establish equivalent prescribed doses, supply or care. Confirm the selected product, full payment obligation and next charge.
At unchanged rates, a twelve-month illustration is about $2,388 at Gala against $3,900 at Pallas Health — a difference of $1,512. This is not a quote for a year of care: actual charges depend on prescribed supply, purchase terms and renewals.
| Gala | Pallas Health | |
|---|---|---|
| Published price | $199/mo | $325/mo |
| Where you can use it | 50 states | 51 jurisdictions |
What neither of them tells you
A comparison that only reports differences implies everything else is settled. Here it is not.
- Both sell a compounded drug and neither names the pharmacy that compounds it.
Before you choose either
The providers describe different service areas. Pallas Health lists 1 that Gala does not list — DC. Confirm your location and selected medication directly. A provider-wide footprint does not establish every treatment’s availability.
Whether these two publish a milligram dose is not settled in our records for both of them, so treat the two prices as not yet comparable and ask each what dose the monthly figure buys. Set the answers against every published price we hold — a lower monthly price at a smaller dose is not the cheaper option.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.